Associate Professor Aude Fahrer
Areas of expertise
- Immunology 1107
- Tumour Immunology 110709
- Immunogenetics (Incl. Genetic Immunology) 110706
- Gene Expression (Incl. Microarray And Other Genome Wide Approaches) 060405
Biography
Dr Fahrer's major research interests are in immunology, cancer immunotherapy and bioinformatics. Aude Fahrer received her B.Sc. (Hons.) and Ph.D. degrees from the University of Melbourne, in viral immunology. Her first postdoctoral position was at Stanford University U.S.A.. During this time she published on gamma delta T cells and also in the field of oral tolerance and was able to make use of several emerging technologies, in particular MHC tetramers for staining antigen-specific T cells, and microarray technology. Her second postdoctoral position was at the John Curtin School at ANU, where she worked on mouse models of immunological defects, identifying the first mutation in a chromosome condensin protein leading to defective T cell development. Her laboratory at the Research School of Biology currently works on two areas: 1) The characterisation of novel proteins involved in immunology and cancer, following our publication of over 2000 predicted novel proteins in the human and mouse genomes. 2) The development of a novel cancer immunotherapy (for which clinical trial approval has recently been granted).
Dr. Fahrer also has a strong commitment to teaching. She currently convenes the third year course "BIOL3141 Infection and immunity", and also lectures to first year biology, third year immunology, and to medical school students.
Publications
- Almonte, A, Cavic, G, Neeman, T et al. 2022, 'Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience', Journal for ImmunoTherapy of Cancer, vol. 10, no. 11.
- Carroll, C, Andrew, E, Malik, L et al. 2021, 'Simple and effective bacterial-based intratumoral cancer immunotherapy', Journal for ImmunoTherapy of Cancer, vol. 9, no. 9.
- Almonte, A, Rangarajan, H, Yip, D et al. 2020, 'How does the gut microbiome influence immune checkpoint blockade therapy?', Immunology and Cell Biology, vol. Online.
- Wang, J, Gross, G, Andrew, E et al. 2019, 'A predicted novel protein isoform of HOXA9', Leukemia Research, vol. 82, pp. 7-10.
- Carroll, C, Altin, J, Neeman, T et al 2015, 'Repeated fine-needle aspiration of solid tumours in mice allows the identification of multiple infiltrating immune cell types', Journal of Immunological Methods, vol. 425, pp. 102-107.
- Wilson, L, Spriggs, A, Taylor, J et al 2014, 'A novel splicing outcome reveals more than 2000 new mammalian protein isoforms', Bioinformatics, vol. 30, no. 2, pp. 151-156.
- Wilson, L & Fahrer, A 2013, 'Condensins, Chromatin Remodeling and Gene Transcription', in Danuta Radzioch (ed.), Chromatin Remodelling, InTech Open Access Publisher, Rijeka, Croatia, pp. 77-89.
- Pok, S, Wen, V, Shackel, N et al 2013, 'Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis', Journal of Gastroenterology and Hepatology, vol. 28, no. 9, pp. 1545-1554.
- Condensins, Chromatin Remodeling and Gene Transcription Wilson, L.O; Fahrer, A.M. in Chromatin Remodelling, DRadzioch (Ed.), InTech. 978-953-51-1087-3 Published: 2013
- Fahrer, A 2012, 'A proposal for a simple and inexpensive therapeutic cancer vaccine', Immunology and Cell Biology, vol. 90, no. 3, pp. 310-313.
- Theodoratos, A, Wilson, L, Gosling, K et al. 2012, 'Splice variants of the condensin II gene Ncaph2 include alternative reading frame translations of exon 1', The FEBS Journal, vol. 279, no. 8, pp. 1422-1432.
- Theodoratos, A., Whittle, B., Enders, A., Tscharke, D. C., Roots, C. M., Goodnow, C. C. & Fahrer, A. M. 2010. 'Mouse strains with point mutations in TAP1 and TAP2', Immunology and Cell Biology, vol. 88, pp. 72-78.
- Yuen, T, Flesch, I, Noel, N et al 2010, 'Analysis of A47, an Immunoprevalent Protein of Vaccinia Virus, leads to a reevaluation of the total antiviral CD8+ T cell response', Journal of Virology, vol. 84, no. 19, pp. 10220-10229.
- Gosling, K, Goodnow, C, Verma, N et al 2008, 'Defective T-cell function leading to reduced antibody production in a kleisin-beta mutant mouse', Immunology, vol. 125, no. 2, pp. 208-217.
- Liston, A, Hardy, K, Pittelkow, Y et al 2007, 'Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling', Genome Biology, vol. 8, no. 1, pp. R12.
- Gosling, K, Makaroff, L, Theodoratos, A et al. 2007, 'A mutation in a chromosome condensin II subunit, kleisin, specifically disrupts T cell development', PNAS - Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 30, pp. 12445-12450.
- Liston, A, Lesage, S, Gray, D et al 2004, 'Generalized resistance to thymic deletion in the NOD mouse: A polygenic trait characterized by defective induction of Bim', Immunity, vol. 21, no. 6, pp. 817-830.
- Fahrer, A, Bazan, J, Papathanasiou, P et al. 2001, 'A genomic view of immunology', Nature, vol. 409, no. 6822, pp. 836-838.
- Fahrer, A, Konigshofer, Y, Kerr, E et al 2001, 'Attributes of gammadelta intraepithelial lymphocytes as suggested by their transcriptional profile', PNAS - Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 10261-6.
- Crowley, M, Fahrer, A, Baumgarth, N et al 2000, 'A population of muring gamma delta T cells that recognize an inducible MHC class Ib moleculae', Science, vol. 287, pp. 314-316.
Projects and Grants
Grants information is drawn from ARIES. To add or update Projects or Grants information please contact your College Research Office.
- EVEREST study: Evaluation of COVID-19 Vaccination Efficacy and Rare Events in Solid Tumours (Secondary Investigator)
- Replacing animal derived antibodies with synthetic nanobodies using yeast surfacedisplayin the fields of structural biology, biotechnology and me (Secondary Investigator)
- Sewerage Surveillance for SARS-CoV-2 in the ACT (Secondary Investigator)
- Cancer Immunotherapy - A paradigm shift in checkpoint inhibitors (Primary Investigator)
